Phosphorus Containing Patents (Class 514/48)
-
Patent number: 8563530Abstract: Disclosed herein is a compound represented by formula 1 or its hydrate thereof in crystalline or crystal-like form.Type: GrantFiled: March 31, 2011Date of Patent: October 22, 2013Assignee: Gilead Pharmassel LLCInventors: Wonsuk Chang, Devan Naduthambi, Dhanapalan Nagarathnam, Ganapati Reddy Pamulapati, Bruce S. Ross, Michael Joseph Sofia, Hai-Ren Zhang
-
Publication number: 20130266591Abstract: The present invention relates to the use of a tri-substituted glycerol compound for the manufacture of a medicament for the treatment of hematological malignancies. The invention also refers to a kit-of-parts comprising such a medicament. Finally, the invention also relates to a corresponding method for the treatment of such conditions as well as to an in vitro method for determining the susceptibility of such malignant cells to a medicament as defined in the invention.Type: ApplicationFiled: June 5, 2013Publication date: October 10, 2013Inventors: Axel Rolf Zander, Francis Ayuk Ayuketang, Wolfgang Richter, Lutz Weber
-
Patent number: 8551973Abstract: A purified compound having activity against hepatitis C virus is disclosed.Type: GrantFiled: December 23, 2009Date of Patent: October 8, 2013Assignee: Gilead Pharmasset LLCInventors: Donghui Bao, Wonsuk Chang, Dhanapalan Nagarathnam, Michael Joseph Sofia
-
Publication number: 20130252917Abstract: The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic Lymphoma (SLL) and multiple myeloma.Type: ApplicationFiled: September 30, 2011Publication date: September 26, 2013Applicant: Portola Pharmaceuticals, Inc.Inventors: Uma Sinha, Anjali Pandey
-
Publication number: 20130244966Abstract: The invention relates to fatty acid antiviral conjugates; compositions comprising an effective amount of a fatty acid antiviral conjugate; and methods for treating or preventing a viral infection comprising the administration of an effective amount of a fatty acid antiviral conjugate.Type: ApplicationFiled: December 12, 2012Publication date: September 19, 2013Applicant: CATABASIS PHARMACEUTICALS, INC.Inventors: Jill C. Milne, Michael R. Jirousek, Chi B. Vu, Allison Wensley, Amal Ting
-
Publication number: 20130237493Abstract: The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic Lymphoma (SLL) and multiple myeloma.Type: ApplicationFiled: September 30, 2011Publication date: September 12, 2013Applicant: Portola Pharmaceuticals, Inc.Inventors: Uma Sinha, Anjali Pandey
-
Publication number: 20130224310Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyses pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes.Type: ApplicationFiled: June 5, 2012Publication date: August 29, 2013Applicant: Emory UniversityInventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
-
Publication number: 20130225519Abstract: A nucleoside compound having activity against hepatitis C virus is disclosed.Type: ApplicationFiled: February 25, 2013Publication date: August 29, 2013Applicant: GILEAD PHARMASSET LLCInventor: GILEAD PHARMASSET LLC
-
Patent number: 8513205Abstract: The present invention relates to compounds, in particular, dual antagonists comprising a nucleoside reverse transcriptase inhibitor (NRTI) or a nucleoside competitive reverse transcriptase inhibitor and a non-nucleoside reverse transcriptase inhibitor (NNRTI), linked together using a chemical linker, which may be used to inhibit HIV (HIV-1) reverse transcriptase and in the treatment of HIV infections, more severe cases of HIV infections, including ARC and AIDS, including reducing the likelihood of these infections and disease states.Type: GrantFiled: April 9, 2009Date of Patent: August 20, 2013Assignees: Yale University, University of Cape TownInventors: Karen S. Anderson, Roger Hunter
-
Patent number: 8507460Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: October 12, 2012Date of Patent: August 13, 2013Assignee: Idenix Pharmaceuticals, Inc.Inventors: Dominique Surleraux, Cyril B. Dousson, Christophe Claude Parsy
-
Publication number: 20130202611Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.Type: ApplicationFiled: January 8, 2013Publication date: August 8, 2013Applicant: Pharmacyclics, Inc.Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
-
Publication number: 20130203694Abstract: Rel proteins as a novel therapeutic agent for treating bacterial threats. More specifically, a novel class of compounds of Formula (I) as disclosed herein which possess anti-bacterial activity and which inhibit RelA, RelSeq or RelSpo synthetic activity or bacterial spore formation. Also, pharmaceutical compositions of such compounds and a method of combating bacteria, or treating bacterial infections, by administering to a subject in need thereof such compounds or pharmaceutical compositions.Type: ApplicationFiled: August 3, 2011Publication date: August 8, 2013Applicant: YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Ezequiel Wexselblatt, Joshua Katzhendler, Gad Glaser, Sigal Ben Yehuda, Roee Vidavski, Hafiz Mawasi, Ilana Kaspy, Yaara Oppenheimer-Shaanan
-
Patent number: 8501709Abstract: The invention is directed to phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base, as well as pharmaceutical compositions thereof. These compounds, which can be described by general formula (II), are useful for the treatment of retroviral infection, e.g., HIV (Human Immunodeficiency Virus) infection in a mammal. The invention also features synthetic intermediates for the preparation of phosphonate nucleosides.Type: GrantFiled: November 8, 2011Date of Patent: August 6, 2013Assignee: K.U.Leuven Research & DevelopmentInventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
-
Publication number: 20130190265Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.Type: ApplicationFiled: March 9, 2013Publication date: July 25, 2013Applicant: THE MEDICINES COMPANYInventor: THE MEDICINES COMPANY
-
Publication number: 20130172286Abstract: This invention relates to a functional food supplement, specifically intended to supplement the enteral or oral nutrition of patients with neurological or neurodegenerative alterations, and for the prevention of cognitive or behaviour disorders, especially in the case of elderly persons, where the functional ingredient especially conceived for the nourishment of patients suffering from, or prone to neurological or neurodegenerative alterations, cognitive deterioration or behaviour disorders comprises a mixture of UMP (uridine monophosphate or uridine) and/or IMP (inosine monophosphate or inosine), vitamins of the B group (B1, B6, B9 and B7), phospholipids and gangliosides and sialic acid, as well as a large amount of DHA.Type: ApplicationFiled: March 31, 2010Publication date: July 4, 2013Applicant: VEGENAT, S.A.Inventors: Angel Gil Hernandez, Paloma San Roman Pais, Milagros Perez Rodriguez
-
Publication number: 20130172239Abstract: The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.Type: ApplicationFiled: December 18, 2012Publication date: July 4, 2013Applicant: AbbVie Inc.Inventor: AbbVie Inc.
-
Publication number: 20130172287Abstract: An agent for treatment of dry eye comprising a combination of a P2Y2 receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, which agent has a dosage form of an ophthalmic agent, can promote the secretion of tear remarkably and can improve corneal epithelial disorders remarkably, and is therefore expected to be a novel agent for treatment of dry eye.Type: ApplicationFiled: September 9, 2011Publication date: July 4, 2013Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Yuko Shichijo, Atsuyoshi Dota, Takashi Nagano, Masatsugu Nakamura, Asuka Sakamoto
-
Publication number: 20130165400Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.Type: ApplicationFiled: December 20, 2012Publication date: June 27, 2013Applicant: ALIOS BIOPHARMA, INC.Inventor: Alios BioPharma, Inc.
-
Publication number: 20130164261Abstract: Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.Type: ApplicationFiled: December 20, 2012Publication date: June 27, 2013Applicant: ALIOS BIOPHARMA, INC.Inventor: ALIOS BIOPHARMA, INC.
-
Patent number: 8461123Abstract: Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2?-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders.Type: GrantFiled: February 9, 2010Date of Patent: June 11, 2013Assignee: Astex Pharmaceuticals, Inc.Inventors: Pasit Phiasivongsa, Sanjeev Redkar
-
Patent number: 8450293Abstract: The invention provides analogs cyclic diguanosine monophosphate (c-di-GMP) having different substituents at the guanine C8 position.Type: GrantFiled: August 10, 2011Date of Patent: May 28, 2013Assignee: Rutgers, The State University of New JerseyInventors: Roger A. Jones, Elizabeth Veliath
-
Publication number: 20130131007Abstract: This disclosure provides compositions of vitamin B12, and methods of treatment or amelioration of a disease associated with vitamin B12 deficiency. The composition can take the form of a solid, semi-solid, gummy, or chewable lozenge. The composition can also take the form of a troche, a candy, a wafer, an orally disintegrating tablet, a sublingual tablet, a buccal tablet, a buccal patch, an oral dissolvable film, an aerosol or spray, a lip balm, and chewing gum.Type: ApplicationFiled: December 21, 2012Publication date: May 23, 2013Applicant: BEBAAS, INC.Inventor: Bebaas, Inc.
-
Patent number: 8440640Abstract: The invention provides methods for, and compositions effective for, treating obesity, inhibiting weight gain, treating diabetes mellitus, inhibiting atherosclerosis and treating related disorders and conditions comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient. The compound capable of inhibiting AC5 may be administered singly or in combination with another agent. In some embodiments, the AC5 inhibiting compound is 9-?-D-arabinofuranosyladenine (AraAde). The compounds may be administered in an amount of about 1 to about 200 mg/kg/day, about 1 to about 100 mg/kg/day, about 10 to about 80 mg/kg/day, about 12 to about 40 mg/kg/day or about 15 to about 25 mg/kg/day. In some embodiments, the compound is administered orally.Type: GrantFiled: November 18, 2009Date of Patent: May 14, 2013Assignee: University of Medicine and Dentistry of New JerseyInventor: Stephen F. Vatner
-
Publication number: 20130108583Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:Type: ApplicationFiled: May 18, 2012Publication date: May 2, 2013Inventors: Alfredo C. Castro, Michael J. Grogan, William Matsui, Karen J. McGovern, Martin R. Tremblay
-
Publication number: 20130102558Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: ApplicationFiled: September 4, 2012Publication date: April 25, 2013Applicant: ABBVIE INC.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
-
Publication number: 20130102526Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: ApplicationFiled: October 19, 2012Publication date: April 25, 2013Applicant: ABBVIE INC.Inventor: ABBVIE INC.
-
Publication number: 20130095064Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections.Type: ApplicationFiled: October 12, 2012Publication date: April 18, 2013Applicant: Idenix Pharmaceuticals, Inc.Inventor: Idenix Pharmaceuticals, Inc.
-
Publication number: 20130090302Abstract: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: September 25, 2012Publication date: April 11, 2013Applicant: Gilead Sciences, Inc.Inventor: Gilead Sciences, Inc.
-
Patent number: 8404651Abstract: The present invention provides compositions methods for treating susceptible viral infections, especially hepatitis C viral (HCV) infections as well as co infections of HCV with other viruses such as HBV and/or HIV. In one embodiment, the present invention provides compositions having the formula (I) and their use in treating viral infections: or a pharmaceutically acceptable salt, ester, stereoisomer, tautomers, solvate, prodrug, or combination thereof.Type: GrantFiled: October 4, 2010Date of Patent: March 26, 2013Assignee: Spring Bank Pharmaceuticals, Inc.Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
-
Patent number: 8399428Abstract: The invention provides a compound of formula (I), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.Type: GrantFiled: December 8, 2005Date of Patent: March 19, 2013Assignee: Regents of the University of MinnesotaInventor: Carston R. Wagner
-
Publication number: 20130064793Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: September 11, 2012Publication date: March 14, 2013Applicant: IDENIX PHARMACEUTICALS, INC.Inventors: Dominique SURLERAUX, Cyril B. DOUSSON, David DUKHAN, Claire PIERRA
-
Publication number: 20130064789Abstract: The present invention relates to hairy cell leukemia biomarkers and methods of utilizing these biomarkers to diagnose and/or treat hairy cell leukemia.Type: ApplicationFiled: May 10, 2012Publication date: March 14, 2013Inventors: Brunangelo Falini, Raul Rabadan, Enrico Tiacci
-
Publication number: 20130064794Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: September 11, 2012Publication date: March 14, 2013Applicant: IDENIX PHARMACEUTICALS, INC.Inventors: Dominique Surleraux, Cyril B. Dousson, Gilles Gosselin, David Dukhan, Claire Pierra, Jerome Peyronnet
-
Publication number: 20130059806Abstract: This disclosure describes methods of screening for compounds that disrupt the interaction between DNMT1 and the gamma-globin promoter or between LSD-1 and the gamma-globin promoter. This disclosure describes methods of screening for compounds that de-repress the gamma-globin gene.Type: ApplicationFiled: May 24, 2012Publication date: March 7, 2013Inventors: James Douglas Engel, Osamu Tanabe, Lihong Shi
-
Patent number: 8372980Abstract: Fused-ring, heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein ?represents an optional double bond, and wherein An, En, Mn, Gn, Jn, R3, n7, R8, R9, R10, R11, R32, R33, X, Y, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.Type: GrantFiled: July 22, 2011Date of Patent: February 12, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Mariappan V. Chelliah, Samuel Chackalamannil
-
Patent number: 8361988Abstract: The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3? position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.Type: GrantFiled: January 17, 2008Date of Patent: January 29, 2013Assignee: Institut de Recherches Cliniques de MontrealInventor: Yvan Guindon
-
Publication number: 20130017171Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: ApplicationFiled: September 20, 2012Publication date: January 17, 2013Applicants: UNIVERSITA DEGLI STUDI DI CAGLIARI, IDENIX PHARMACEUTICALS, INC.Inventors: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari
-
Patent number: 8343937Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: GrantFiled: September 25, 2006Date of Patent: January 1, 2013Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di CagliariInventors: Jean-Pierre Sommadossi, Paulo LaColla
-
Patent number: 8334270Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.Type: GrantFiled: May 3, 2011Date of Patent: December 18, 2012Assignee: Gilead Pharmasset LLCInventors: Michael Joseph Sofia, Jinfa Du, Peiyuan Wang, Dhanapalan Nagarathnam
-
Publication number: 20120282172Abstract: The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.Type: ApplicationFiled: May 9, 2012Publication date: November 8, 2012Applicants: Centro de Neurociencias e Biologia Celular, Universidade de CoimbraInventors: João Nuno Sereno de Almeida Moreira, Vera Lúcia Dantas Nunes Caldeira de Moura, Sérgio Paulo de Magalhães Simões, Maria da Conceição Monteiro Pedroso de Lima
-
Patent number: 8299038Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: GrantFiled: July 16, 2009Date of Patent: October 30, 2012Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di CagliariInventors: Jean-Pierre Sommadossi, Paulo LaColla
-
Publication number: 20120270830Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including theanine and one or more exogenous nucleotides. The nutritional compositions can be specifically used to treat functional bowel disorders, including inflammatory bowel syndrome.Type: ApplicationFiled: August 23, 2010Publication date: October 25, 2012Applicant: NESTEC S.A.Inventors: Norman Alan Greenberg, Peter Geoffrey McLean, Magali Faure
-
Publication number: 20120264709Abstract: The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: November 14, 2011Publication date: October 18, 2012Applicant: Spring Bank Pharmaceuticals, Inc.Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
-
Publication number: 20120258928Abstract: Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure:Type: ApplicationFiled: April 5, 2012Publication date: October 11, 2012Applicant: GILEAD PHARMASSET LLCInventors: JINFA DU, DHANAPALAN NAGARATHNAM, GANAPATI REDDY PAMULAPATI, BRUCE S. ROSS, MICHAEL JOSEPH SOFIA
-
Publication number: 20120252752Abstract: Bacterial virulence is repressed by compositions and methods for activating permanently a repressor of virulence factors. Compositions provided contain at least one non-metabolizable analog of guanine, guanosine, isoleucine and valine.Type: ApplicationFiled: May 11, 2012Publication date: October 4, 2012Inventor: Abraham L. Sonenshein
-
Publication number: 20120251487Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: March 30, 2012Publication date: October 4, 2012Inventor: Dominique SURLERAUX
-
Patent number: 8242087Abstract: This invention relates to novel phosphate-modified nucleosides, and methods for producing them, being useful for the prevention or treatment of a viral infection in a mammal, and for preparing oligonucleotides by DNA/RNA polymerase-dependent amplification, e.g. PCR.Type: GrantFiled: August 27, 2009Date of Patent: August 14, 2012Assignee: K.U.Leuven Research & DevelopmentInventors: Olga Adelfinskaya, Piet Herdewijn
-
Publication number: 20120201747Abstract: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.Type: ApplicationFiled: February 2, 2012Publication date: August 9, 2012Applicant: POP TEST CORTISOL LLCInventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
-
Publication number: 20120196826Abstract: The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune disease.Type: ApplicationFiled: March 6, 2012Publication date: August 2, 2012Inventor: Steven Baranowitz
-
Publication number: 20120195870Abstract: The present invention relates primarily to the use of locust tree (Gleditsia) wood or heartwood extracts as anti-cellulite active substances. The present invention further relates to certain locust-tree wood extracts and mixtures containing locust-tree wood extracts and corresponding cosmetic, dermatological or pharmaceutical preparations, which are suitable in particular for the prevention and treatment of cellulite in humans.Type: ApplicationFiled: February 2, 2012Publication date: August 2, 2012Applicant: SYMRISE AGInventors: Martina Herrmann, Holger Joppe, Imke Meyer, Karin Schaper, Thomas Küper, Julia Betke